Diabetic Retinopathy

A wholesome medicine to treat diabetic retinopathy & complications and improve quality of life.

Current scenario of diabetic retinopathy management (DR)

Diabetic Retinopathy: A primary cause of vision loss in adults aged 20-74 years

Amongst the approx. 422 million people with diabetes mellitus worldwide, 35% (145 million) have form DR *1
1.06% of blindness world-wide could be attributed to DR *2
11% (45 million) have vision-threatening DR *3

*1- Lee et al, 2015, Ting et al; 2016, Yau et al; 2012

*2- Flaxman et al; 2017

*3- Lee et al, 2015, Yau et al, 2012

Current solutions and practices

Argon-laser photocoagulation

Anti-VEGF injections

Intravitreal corticosteroids

Vitreoretinal surgery

Limitations of current solutions (Nentwich & Ulbig):

Adverse reactions associated with medication:

1. Vision loss, scar, bleeding in the eye, Reduced colored vision.

2. Elevated intra-ocular pressure (glaucoma).

3. Cataract formation.

4. Recurrent hemorrhage.

5. Retinal detachment.

Adverse reaction associated with route of administration:

1. Endophthalmitis.

2. Vitreous hemorrhage.

3. Retinal detachment.

4. Eye irritation/discomfort.

5. Floaters or feeling of having something in eye.

6. Watery or dry itchy eyes.

7. Scar formed from treatment.

Oral route of administration of medicine along with unequal combination of gritha and honey, is the safest route.

Introducing our medicine

-0%

Trinetra Atibala

Quick View

Add to wishlist

Diabetic Retinopathy

Add to bag - ₹200.00

About this medicine:

Enhances Best Corrected Visual Acuity (BCVA)
Improves Contrast Sensitivity (CS)
Gradually improves Macular edema without exacerbations
Stabilizes Microaneurysm by slowing disease progression
Decreases Retinal hemorrhage and total Neo-vascularization sustainably

A study was conducted by administration of Trinetra Atibala for 90 days and below is the Optical coherence tomography (OCT) images to show changes in macular edema observed after 90 treatment